Market revenue in 2022 | USD 1,619.1 million |
Market revenue in 2030 | USD 2,447.4 million |
Growth rate | 5.3% (CAGR from 2022 to 2030) |
Largest segment | Branded |
Fastest growing segment | Generics |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Branded, Generics |
Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 62.21% in 2022. Horizon Databook has segmented the China gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
China is anticipated to witness substantial market growth in the near future owing to rise in the prevalence of gastrointestinal diseases due to various socioeconomic factors, increase in R&D activities, and growing investments in healthcare industry.
In addition, increase in product approvals is also expected to fuel the market growth in the country. For instance, in January 2019, Ironwood Pharmaceuticals announced that its drug Linzess received approval from the National Medical Products Administration for the treatment of IBS in adults.
The drug was jointly developed by Ironwood and AstraZeneca, with the latter being responsible for commercialization of the drug in the country. Thus, rise in regulatory approvals of drugs can lead to rise in the options for the treatment of various IBS-related symptoms.
Horizon Databook provides a detailed overview of country-level data and insights on the China gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into China gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account